Yamada Shohei, Yazawa Masahiko, Yamamoto Makoto, Koitabashi Kenichiro, Ichikawa Daisuke, Koike Jyunki, Shibagaki Yugo
Division of Nephrology and Hypertension, Department of Internal Medicine, St. Marianna University School of Medicine, 2-16-1 Sugao, Miyamae-Ku, Kawasaki, 216-8511, Japan.
Department of Pathology, Kawasaki Municipal Tama Hospital, 1-30-37 Syukugawara, Tama-Ku, Kawasaki, 214-8525, Japan.
CEN Case Rep. 2019 Aug;8(3):188-193. doi: 10.1007/s13730-019-00390-8. Epub 2019 Mar 2.
Oxaliplatin, a third-generation platinum agent, has been used for the treatment of colon, pancreatic, and stomach cancers in recent years. It carries a reduced risk of acute kidney injury (AKI) compared to the previous platinum agents, including cisplatin and carboplatin. Several cases of oxaliplatin-induced acute tubular necrosis (ATN) have been reported; however, only one case has been reported as acute tubulointerstitial nephritis (ATIN) histopathologically. Here, we present a case of biopsy-proven and dialysis-dependent ATIN, which dramatically resolved with steroid therapy. The patient was a 67-year-old male who had undergone chemotherapy for colon adenocarcinoma. He suddenly developed shaking chills, fever, and hot flashes at the end of the 18th 5-fluorouracil (5-FU)/L-leucovorin/oxaliplatin administration, and was admitted to our hospital. On the 4th day of hospitalization, severe renal dysfunction (creatinine 6.5 mg/dL) was observed. As oliguria continued, we initiated hemodialysis therapy on the 6th day of hospitalization. Drug-induced ATIN was strongly suspected due to the history of multiple exposures to oxaliplatin with allergic reaction and sterile pyuria. We began steroid therapy on the 8th day of hospitalization. Subsequently, renal biopsy was performed and the diagnosis of ATIN was made. The patient's renal function gradually improved, and 6 months later, it had returned to baseline. Our case demonstrates that we should consider not only ATN, but also ATIN, as potential presentations of oxaliplatin-induced AKI.
奥沙利铂是一种第三代铂类药物,近年来已用于治疗结肠癌、胰腺癌和胃癌。与包括顺铂和卡铂在内的先前铂类药物相比,它导致急性肾损伤(AKI)的风险较低。已有数例奥沙利铂诱导的急性肾小管坏死(ATN)的报道;然而,经组织病理学证实为急性肾小管间质性肾炎(ATIN)的仅报道过1例。在此,我们报告1例经活检证实且依赖透析的ATIN病例,该病例经类固醇治疗后显著缓解。患者为一名67岁男性,曾接受过结肠癌化疗。在第18次5-氟尿嘧啶(5-FU)/亚叶酸钙/奥沙利铂给药结束时,他突然出现寒战、发热和潮热,并入住我院。住院第4天,观察到严重肾功能不全(肌酐6.5mg/dL)。由于少尿持续存在,我们在住院第6天开始进行血液透析治疗。鉴于多次接触奥沙利铂并有过敏反应和无菌性脓尿史,强烈怀疑是药物性ATIN。我们在住院第8天开始使用类固醇治疗。随后进行了肾活检,并确诊为ATIN。患者的肾功能逐渐改善,6个月后恢复至基线水平。我们的病例表明,对于奥沙利铂诱导的AKI,我们不仅应考虑ATN,还应考虑ATIN这一潜在表现形式。